Market revenue in 2020 | USD 41.1 million |
Market revenue in 2028 | USD 94.5 million |
Growth rate | 11% (CAGR from 2020 to 2028) |
Largest segment | Neurological disorders |
Fastest growing segment | Cancer |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Neurological disorders was the largest segment with a revenue share of 16.06% in 2020. Horizon Databook has segmented the China rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
China’s attempts to shift attention of the of the healthcare system towards diagnosis and treatment of rare diseases remained at the nascent stage. It is estimated that around 20 million individual are living with a rare condition in the country.
As a result, the government has included rare disease management as a public health priority in its 2030 roadmap titled Healthy China 2030. Furthermore, in June 2018, China released its first list of rare diseases in order to enable the patients to find solutions effectively at their local hospitals. In addition.
in February 2019, China announced to establish a national collaborative network of hospitals which would be devoted for diagnosis including early detection and treatment of rare disease diagnosis. This is expected to benefit the diagnostic developers operating in the country over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the China rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into China rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account